A Breakdown of C. R. Bard’s Business Segments


Jun. 1 2016, Published 3:12 p.m. ET

C. R. Bard: Business overview

C. R. Bard (BCR) generates revenues from manufacturing, selling, and marketing medical devices in the following business segments:

  • Vascular
  • Urology
  • Oncology
  • Surgical Specialties
Article continues below advertisement

Vascular devices

The Vascular segment consists of a portfolio of minimally invasive devices for the treatment of heart arrhythmias, ESRD (end stage renal disease) and PVD (peripheral vascular disease) through endovascular devices and grafts.

The Vascular segment accounts for around 28% of the company’s total revenues. Some of the key products in this segment include peripheral angioplasty catheters, peripheral vascular stents, vena cava filters, and drug-coated balloons. Boston Scientific (BSX), St. Jude Medical (STJ), and Abbott (ABT) are some of the major competitors in this space.

Urology devices

C. R. Bard’s Urology segment consists of basic drainage devices, continence devices, urological specialty products, catheter stabilization devices, and targeted temperature management products. The segment accounted for 25% of the company’s total revenues in 2015. The Foley catheter is the company’s key product in the Urology segment. Medtronic and Boston Scientific are C. R. Bard’s major competitors in this segment.

Article continues below advertisement

Oncology segment

The oncology device segment consists of products used for the treatment and management of cancers and related conditions. These products include specialty vascular access ports and catheters used primarily for chemotherapy, ultrasound devices, dialysis access catheters, and PICCs (peripherally inserted central catheters) used for central venous access. The segment’s sales accounted for 27% of C. R. Bard’s total revenues in 2015. Some major competitors in this space include Boston Scientific and Becton, Dickinson and Company.

Surgical Specialties

C. R. Bard’s Surgical Specialties segment accounts for 17% of the company’s total revenues. The segment consists of products and devices used for hernias and soft tissue repairs. C. R. Bard is the leader in the groin hernia repair market. Its product line includes implanted grafts, fixation devices, hemostats, and surgical sealants. Major competitors in this space include Medtronic and Johnson & Johnson. One of the major ETFs with exposure to C. R. Bard is the Health Care Select Sector SPDR ETF (XLV), which has 0.65% of its total holdings in BCR.


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.